...we evaluated the NGS results of 82 melanoma patients from clinical routine in 2017….we investigated their potential as a predictor for resistance to immune checkpoint inhibitors (ICI)...A significantly higher incidence of BRAF V600 mutations and EGFR amplifications, PTEN and TP53 deletions was found in patients with disease progression while on ICI.